Juno Therapeutics (JUNO) : Traders are bullish on Juno Therapeutics (JUNO) as it has outperformed the S&P 500 by a wide margin of 10.38% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.28%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.71% in the last 1 week, and is up 13.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Juno Therapeutics (NASDAQ:JUNO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.61 and $30.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $32.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $31.46, notching a gain of 1.75% for the day. The total traded volume was 2,086,514 . The stock had closed at $30.92 on the previous day.
The stock has recorded a 20-day Moving Average of 6.87% and the 50-Day Moving Average is 15.4%. Juno Therapeutics Inc. has dropped 15.36% during the last 3-month period . Year-to-Date the stock performance stands at -28.45%.
Juno Therapeutics (JUNO) : The highest short term price target forecast on Juno Therapeutics (JUNO) is $80 and the lowest target price is $39. A total of 9 equity analysts are currently covering the company. The average price of all the analysts is $52.67 with a standard deviation of $12.75.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.